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ABSTRACT 
The main aim of this study was to improve the bioavailability of curcumin through buccal route using mucoadhesive drug delivery. Curcumin is 
practically insoluble in water. After oral administration, most part of the drug was metabolism in liver .Therefore  an attempt has been made to 
improve the bioavailability by using different concentration of sodium lauryl sulphate as bioenhancer. Buccal bilayer tablets  were prepared by 
direct compression with different ratio of HPMC.K4M.as bioadhesive polymer and ethyl cellulose as backing layer. The formulation were 
characterized for various physiochehimical parameter such as weight variation, thickness, hardness, fribality, mucoadhisive strength, drug 
content, swelling studies and in vitro diffusion studies. The best mucoadhesive performance and In vitro drug release profile exhibited by 
tablets containing hydroxyproply methylcellulose K4M (5%) and Sodium louryl sulphate (0.1%).To conclude that the formulated 
unidirectional, bilayered, buccoadhesive tablet for curcumin using HPMC as mucoadhesive agent is superior to oral conventional tablet, as it has 
the potential to bypass the first pass metabolism and improve the bioavailability of curcumin.  
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INTRODUCTION 
The requirement for research and development of new 
pharmaceuticals molecules. The safety and potency of 
particular treatment may be improve if its administration 
rate or delivery rates, targeting, monitoring of site is 
controlled. [1]. There are different route of administration of 
drug into the body like oral, sub mucosal, parenteral, 
transdermal, pulmonary etc. Among this route of 
administration oral route is broadly preferred. This route is 
very simple, most economical and noninvasive, now a day 
scientist are trying to develop various technologies to 
incorporate in oral formulations.; a small change in drug 
delivery method can make tremendous difference in  patient 
acceptability and bioavailability. [2]. However, this route 
offers several disadvantages as well like: Sometimes 
inefficient, First pass effect, Irritation to gastric environment, 
Unpleasant taste of drug, Not suitable in case of emergency 
[3] 
 Difficulties associated with parenteral delivery and poor 
oral availability promoted the impetus for exploring another 
routes for the delivery of those drugs. As a result, other 
absorptive mucosa is considered as effective site for drug 
delivery. There are different types of route for drug delivery 
for example mucosal linings of nose, vaginal, ocular, rectal 
and oral cavities this proposes distinctive advantage over 
per-oral administration for systemic effects. Among the 
different buccal mucosa, mucosal routes shows better 
acceptability over smooth muscles and immobile mucosa, so 
it is appropriate for giving in controlled release dosage 
forms [4].  
Curcumin [1, 7-Bis  (4-hydroxy-3- methoxyphenyl)-1,6- 
heptadiene 3,5-dione] is the naturally derived therapeutic 
products, in the current scenario it is very popular in respect 
of research , due to it has various properties. Curcumin is the 
main biologically active curcuminoid of Curcuma longa-a 
herbaceous perennial herb family (Zingiberaceae) [5]. 
Curcumin produce a wide variety of  physiologic activities, 
like anti-inflammatory activity by inhibiting NF-kB; induced 
apoptosis shows antineoplastic activity by arresting cell 
cycle it also inhibit angiogenesis .It possess anti-oxidant 
activity by excluding free radicals and an increasing  
intracellular concentration of glutathione. curcumin also 
shows anti viral and anti hepatotoxic activity. [6]. 
The pharmacokinetic studies of animals shows that 40-85 
percent of oral dose of curcumin passes unchanged through 
the GIT.It is mainly absorbed flavanoid metabolized in the 
intestinal mucosa and liver. It has slow rate of absorption 
due to which is often given in combination with  bromelain 
to increase absorption and to enhanced anti inflammatory 
activity [7]. The main disadvantage associated with oral 
administration of curcumin is high metabolic instability and 
less aqueous solubility due to which its systemic 
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bioavailability is limited. In addition, to this the patient 
shows non compliance for oral curcumin at the high doses 
(>8 g/day) to  overcome these difficulties, new strategies for  
delivery of curcumin are being studied [8]. The present 
study was planned with the aim to formulate mucoadhesive 
buccal tablets of curcumin to improve the solubility and 
dissolution profile. 
MATERIALS AND METHODS 
Methodology 
Pre-compressional Studies 
Curcumin and the selected polymers were subjected to pre-
compressional studies. Identification and purity of curcumin 
was determined by measuring the solubility, melting point, 
determination of λmax. Compatibility of curcumin and 
polymers was examined by the help of FTIR. 
Formulation of Curcumin Buccal Tablets 
All the ingredients except ethyl celluose are passed through 
sieve 80 and gently mixed together in an air tight plastic 
container. Then mixture is lubricated by adding magnesium 
stearate and talc and again blended for 2 min. The mixed 
ingredients are evaluated for precompression parameters, 
followed by direct compression. The weight of the tablets is 
adjusted to 200mg and coated by ethyl cellulose 60 mg to 
keep the unidirectional flow of drug. 
 
Table 1: Formulation Table 
Batch Code F1 F2 F3 F4 
Curcumin 100 100 100 100 
Guar gum 10 20 30 40 
Microcrystalline  
cellulose (MCC) 
15 15 15 15 
PEG – 6000 11 11 11 11 
Piperine 2 2 2 2 
Magnesium Stearate 3 3 3 3 
Talc 2 2 2 2 
Lactose 57 47 37 27 
Ethyl cellulose 60 60 60 60 
Total Weight 260 260 260 260 
 
 
Curcumin Buccal Tablet evaluation 
Uniformity of Weight 
Twenty tablets were selected at a random and weighed 
individually. The average weight was calculated. The 
percentage deviation of tablets was calculated and compared 
with the standard specifications.  
Table 2: Standards for calculating uniformity of weight 
S.No. Average weight of a tablet % Deviation 
1. 80 mg or less ±10 
2. 80-250 mg ±7.5 
3. More than 250 mg ±5 
 
Thickness 
The thickness was measured to determine the uniformity of 
size and shape. Thickness of the Curcumin buccal tablets was 
measured using vernier caliper. 
Hardness 
Hardness is defined as the force required for breaking a 
tablet at diametric compression test and it is termed as 
tablet crushing strength. Hardness of the prepared 
formulations was determined using a tablet hardness tester. 
It was expressed in kp. 
Friability  
Friability of the prepared formulations was determined by 
using a friability tester. Pre- weighed  tablets sample was 
placed in the friability tester, which was then operated for 
25 revolutions for 4 min, tablets were dusted and reweighed. 
The friability of the tablets was calculated using the formula 
mentioned below. 
%Friability = 
                                    
                        
      
Drug Content 
Ten tablets were randomly taken, weighed and powdered. 
The powder weight equivalent to 140 mg of curcumin was 
weighed out and put in 150 ml of methanol and placed in an 
ultra sonicator for 5 min. The sonicated solution was then 
filtered out using a Whatman No. 1 filter paper. The filtered 
solution was then made-up to 250ml using methanol. 5ml 
from the above solution was taken and diluted to 100ml 
with methyl alcohal. The final solution was analyzed using 
U.V. Visible spectrophotometer at 325 nm.  
Swelling Index 
The, previously weighed (w1), tablets were placed 
individually in a petri-dish containing 10ml of distilled 
water. The weight of the tablet (w2) after 30min was noted 
down after wiping the excess water from the tablet using a 
filter paper. The swelling index was calculated using the 
formula.  
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Swelling Index = 
      
  
     
Wash –off Test  
The mucoadhesive properties of the tablets were evaluated 
by wash-off method.  buccal mucosa pieces of goat were 
mounted on the glass slides provided by suitable support. 
After fixing two tablets to this glass slide by pressing them 
onto the pre-wet tissue for 30sec, it was attached to the arm 
of tablet disintegration test apparatus (with the cylindrical 
drug chambers removed) and was run at 37°C in pH 6.8 
buffer. Time taken for the detachment of both the tablets 
was noted down. 
In vitro drug release study 
The dissolution study was carried out by dissolution 
apparatus. The dissolution medium consisted of 900ml of pH 
6.8 phosphate buffer. The temperature was set at 37 ± 0.5°C 
with a revolving speed of 50 rpm. The curcumin buccal 
tablet was allowed to sink to the base of the vessel. Samples 
of 10ml were withdrawn at 10 min interval, filtered and 
analyzed by UV at 425 nm. 
Drug Release Kinetics 
The release of drugs from the tablet can be characterized 
using various kinetic models [9].  
 Zero order equation  
 First order equation  
 Higuchi Kinetics 
 Korsmeyer Peppas equation 
 Hixson and Crowell erosion equation
                                                                         
Table 3: Release mechanism based on n-value 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45< n > 0.89 Anomalous (non-fickian) diffusion 
0.89 Case – II tranport 
N Super case – II transport 
 
Table 4: Parameters of release kinetics 
 Release mechanism Y - axis X - axis 
Zero order Kinetics % Cumulative drug release Time in min 
First order kinetics Log % cumulative drug remaining Time in min 
Higuchi Kinetics % Cumulative drug release Square root of time 
Korsmeyer-Pappas Equation Log cumulative % of drug release Log time 
Hixson and crowell equation Cube root of % drug remaining Time in min 
 
RESULTS AND DISCUSSION 
The curcumin buccal tablet were successfully made – (direct compression method) by using guar gum and piperine as 
excipient. 
Pre-compression Evaluations 
Buccal Tablet Evaluations 
Table 5: Pre-compression parameters 
Code Bulk Density 
(g/cm3) 
Tapped density 
(g/cm3) 
Carr’s index Hausner’s ratio Angle of repose 
F1 0.559 0.722 21.56 1.289 25.000 
F2 0.541 0.689 18.79 1.240 28.594 
F3 0.536 0.693 20.68 1.252 26.215 
F4 0.524 0.697 21.33 1.271 21.371 
 
Pre-compression specifications played an important role in 
enhance the properties of pharmaceuticals preparation 
especially in tablet formulation. This includes Bulk and 
Tapped density/ Carr’s index, Angle of repose and 
Haaunser’s ratio. Before the  tablets formulations the drug 
were tested for above mentioned parameters, it was 
observed that all the results found as per  prescribed limits 
in IP as shown in table 5. For all the formulations bulk 
density was stated to be ranging from (0.524-0.559)gm/cm3, 
tapped density was between (0.689-0.722) gm/cm3and 
angle of repose was found in between (21.371 to 28.594) 
gm/cm3. Carr’s index - (18.79 to 21.56) and Hausner’s - 
(1.240 to 1.289). 
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Post-Compression Evaluation  
Weight variation 
According USP twenty tablets were selected randomly from 
every batch; weighed individually by using analytical 
weighing balance. The average and standard deviation were 
calculated. The average weight of 20 tablets was observed in 
between 379.88 ± 0.287 mg to 380.86 ± 1.096 mg as 
showed in table 6. Weight variation analysis of all batches 
was found within the pharmacopoeial limits; ±7.5% of the 
weight. 
Table 6: Weight Variation Data 
Code Weight variation 
F1 379.33±1.258 
F2 381.50±1.322 
F3 380.34±0.577 
F4 380.50±0.500 
 
 
Fig 1: Weight variation 
Thickness 
The thicknesses of tablet are important for its uniformity of 
tablet size. Tablet width was measured by using (Caliper 
Vernier). 3 tablet average of was taken. The tablet thickness 
must be within ± 5 variation of standard value. The width of 
tablets for every batch ranged in between 3.7±0.054 to 
3.9±0.035 mm (Table 7). This shows proper handling 
characteristics for all batches. 
Table 7: Thickness Testing Data 
Batch Code Thickness 
F1 3.8±0.019 
F2 3.7±0.054 
F3 3.9±0.035 
F4 3.8±0.047 
 
 
Fig 2: Thickness testing interpretation 
 
 
Hardness  
Tablet hardness  indicate that the ability of the tablet to face 
mechanical shocks while handling. It is measured by using 
Monsanto hardness tester. Its unit  expressed in kilo 
gram/cm2. Average of 6 tablet was taken as per  USP norms 
from each formulation.  Hardness of tablets of every batch 
(ranged between 4.0±0.179 to 5.0±0.196 kg/cm2 (Table 
No.8). Its confirm that good mechanical strength for all 
batches. 
Table 8: Hardness Testing Data 
Batch Code Hardness (kg/cm2) 
F1 4.0±0.163 
F2 4.0±0.115 
F3 5.0±0.179 
F4 4.0±0.142 
 
 
Fig 3: Hardness testing interpretation 
Friability 
Friability test is used to determine the loss in weight of 
tablets in container for the duration of transportation.  20 
tablets were initial weight was recorded and load in Roche 
friabilator. It rotates at 25 rpm for 4 minutes. After that 
loaded tablet was taken out and again weight, the difference 
between the weights was recorded .The friability result for 
formulated tablets was observed-(0.41 ± 0.013 to 0.68 ± 
0.012 %) as showing table 9. All the formulated tablets 
showed the percentage friability not more than 1%. 
Table 9: Friability Testing Data 
Batch Code Friability (%) 
F1 0.53±0.011 
F2 0.41±0.013 
F3 0.59±0.014 
F4 0.68±0.012 
 
 
Fig 4: Friability testing interpretation 
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Drug content 
Five tablets from each formulation were taken, crushed and 
mixed. From the mixture of  100mg ;equivalent  mixture was 
extracted carefully within range of pH 6.8 phosphate buffer 
and 3% tween 80.The quantity of drug present in each 
extract wascalculated by using UV spectrophotometer at 
wavelength 425 nm against blank. All the formulated 
mucoadhesive buccal tablets are tested for uniformity of 
drug content. 
Drug content in formulation was observed (96.00±1.410 to 
97.14±1.332 %) which is shown in table 10. 
Table 10: Drug Content Testing Data 
Batch Code Drug Content (%) 
F1 97.14±1.332 
F2 96.24±1.390  
F3 96.00±1.410  
F4 96.11±1.782  
 
 
Fig 5: Drug content testing interpretation 
Swelling Index 
The curcumin mucoadhesive buccal tablets initial weight 
exactly and taken into a petri dish which contains 5ml of pH 
6.8 phosphate buffer, temperature maintained at 37±0.5°C. 
After f 3 hour the tablets were removed from the Petri dish 
and swollen tablets were reweighed (final weight). The 
swelling index was calculated by means of mathematical 
expression .The swelling index of buccal tablets was 
observed in between (8.78±0.874 to 53.70±0.854), at the 
end of 3 hours as showed in table 11. 
Table 11: Swelling index Testing Data 
Batch code Swelling index 
F1 19.66±0.341 
F2 25.48±0.288 
F3 34.17±0.322 
F4 46.89±0.641 
 
 
Fig 6: Swelling Index testing interpretation 
Retention time (In vitro) 
In vitro retention time is determined by goat buccal mucosa 
in modified magnetic stirrer. The  buccal mucosa of goat was 
attached with  glass slide and the curcumin mucoadhesive 
tablet was press on buccal mucosa of goat for 30 seconds, 
which is dip in beaker containing 500ml of pH 6.8 phosphate 
buffer, the temperature maintained at 37±0.5ºC. The 
magnetic beat was rotated at 25 rpm, the experiment was 
continuing till the buccal tablet detached from the goat 
buccal mucosa. The In-vitro residence time of buccal tablets 
was observed (140 minutes to 220 minutes) that is 
considered as good retention time as shown in table 12.  
Table 12: In vitro Retention time 
Batch Code In vitro retention time (min) 
F1 140 
F2 155 
F3 176 
F4 220 
 
 
Fig 7: In vitro retention time interpretation 
In-vitro Drug release 
The drug release studies were performing by using USP II 
dissolution test apparatus (paddle type).the tablet was 
formulated in such manner that drug is release from one 
side only, because it is design for unidirectional 
released.Now, all tablet were placed in 900ml in phosphate 
buffer (pH 6.8) containing 3% tween 80 ,The temperature  
maintain at 37±0.5°C; 4.0 hours. Now start the machine and 
set the paddle on 100 rpm. After every 30 min take 5 ml 
sample .Maintained  dissolution medium with fresh buffer 
for analysis of drug content. Now check on UV 
spectrophotometer at 425nm. The drug release by 
formulated tablets is (82.02±0.33%) which is showed by 
formulation F3 within 4.0 hours. 
Note-UV spectrophotometer is used for drug release here 
because there is no specific dissolution test available for  
curcumin mucco adhesive tablets. 
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Table 13: Drug release data (In vitro) 
S.No. Time (min) Cumulative % drug release 
F1 F2 F3 F4 
1 0 0 0 0 0 
2 30 24.52±0.72  26.74±0.46 12.07±0.29 19.21±0.12 
3 60 59.26±0.28 39.07±0.22 25.94±0.71 23.01±0.25 
4 90 76.05±0.34 46.31±0.53 36.08±0.66 32.84±0.14 
5 120 94.19±0.87 62.92±0.91 42.15±0.85 38.29±0.16 
6 150 - 80.62±0.35 57.33±0.22 44.59±0.38 
7 180 - 92.25±0.57 68.79±0.11 49.60±0.65 
8 210 -  72.48±0.95 57.03±0.28 
9 240 -  82.02±0.33 67.22±0.91 
 
 
 
Fig 8: In vitro drug release interpretation 
Mathematical expression for kinetic assessment of drug 
release mechanism 
The release data obtained from in vitro dissolution studies 
were fitted to five different mathematical models namely, 0 
order, 1st order, Higuchi’s model, Korsmeyer peppas &  
Hixson-crowell to find mechanism of drug release. 
Correlation coefficients (R2) obtained from regressed plots 
of different kinetic models such as 0 order, 1st order, 
Higuchi’s model, Korsmeyer peppas and Hixson-crowell 
model are also mentioned. The correlation coefficients (R2) 
were used as an indication of the best fit, for each of the 
models considered. The correlation coefficients (R2) was 
obtained in 0 order, 1st  order, Higuchi model, Korsmeyer 
peppas and Hixson-crowell model of formulation F3 shown 
in fig. 6.13-6.17 were 0.989, 0.969, 0.939, 0.996, 0.786. In 
this formulation Korsmeyer peppas model best explain in 
vitro drug release ,because best linearity was found in 
Korsmeyer peppas model equation plot (R2 = 0.998) shown 
in fig. 9. 
Table 14: In vitro release data of F3: Zero order kinetics 
Time (min) Percentage cumulative drug 
release 
0 0 
30 12.07 
60 25.94 
90 36.08 
120 42.15 
150 57.33 
180 68.79 
210 72.48 
240 82.02 
 
 
Fig 9: Plot for zero order kinetic 
Table 15: release data of formulation F3: First order 
kinetics (In vitro) 
Time (min) Log % cumulative drug 
remaining 
0 2 
30 1.94 
60 1.86 
90 1.80 
120 1.76 
150 1.63 
180 1.49 
210 1.43 
240 1.25 
 
 
Fig 10: Plot for first order kinetics 
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Table 16: In vitro release data of F3: Higuchi model 
release kinetics 
% Cumulative drug release SQRT 
0 0 
12.07 5.47722 
25.94 7.74596 
36.08 9.48683 
42.15 10.95445 
57.33 12.24744 
68.79 13.41640 
72.48 14.49137 
82.02 15.49193 
 
 
Fig 11: Plot of Higuchi model release kinetics 
Table 17: In vitro release data of F3: Koresmeyer Peppas 
model  
Log Time Log % CDR 
0 0 
1.477 1.081 
1.778 1.406 
1.954 1.557 
2.079 1.624 
2.176 1.758 
2.255 1.837 
2.322 1.860 
2.380 1.913 
  
 
Figure 12: Plot of Korsmeyer peppas model release 
kinetics 
Table 18: In vitro release data of F3: Hixson Crowell 
model 
Time (min) Cube root of % cumulative drug 
release 
0 0 
30 2.29 
60 2.96 
90 3.30 
120 3.48 
150 3.85 
180 4.09 
210 4.16 
240 4.64 
 
 
       Figure 13: Plot of Hixson crowell model release 
kinetics
 
Table 19: Kinetic assessment of dissolution data of curcumin mucoadhesive buccal tablet formulation   
Zero order model First order model Higuchi model Koresmeyer 
peppas 
Hixson crowell 
R2 R2 R2 R2 R2 
0.989 0.969 0.939 0.996 0.786 
 
CONCLUSION 
On the basis of this research work we can conclude that, 
delivery through buccal route is a promising way to enhance 
the bioavailability of poorly water soluble/ water insoluble 
drugs. Buccal drug delivery helps in eliminating the first 
pass metabolism of various drugs and directly provides the 
drug to the systemic circulation. Incorporation of 
hydrophilic polymer enhances the efficacy of this system. 
This opens an extensive area for research in this field which 
will be beneficial in overcoming the bioavailability problems 
of existing drugs as well as new molecules because as per 
statistics 70% of new developed compounds are facing the 
problem of poor bioavailability due to which they cannot 
reach the development pipeline. Therefore, further research 
needs to be done to study this area extensively.
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